A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

British Journal of Cancer

Volumn 106, Issue 12, 2012, Pages 1934-1939

  Nakai, Y ^a   Isayama, H ^a   Sasaki, T ^a   Sasahira, N ^a   Tsujino, T ^a   Toda, N ^b   Kogure, H ^c   Matsubara, S ^c   Ito, Y ^d   Togawa, O ^e   Arizumi, T ^f   Hirano, K ^a   Tada, M ^a   Omata, M ^g   Koike, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MITSUI MEMORIAL HOSPITAL   (Japan)

^c The Mutualaid Association of Public School Teachers)   (Japan)

^d Japanese Red Central Blood Center   (Japan)

^e JR Tokyo General Hospital   (Japan)

^f TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^g YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

chemotherapy; gemcitabine; pancreatic cancer; randomised controlled trial; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; TEGAFUR;

EID: 84862006429     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.183     Document Type: Article

References (25)

1. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-2413 (Pubitemid 27251144)
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-1825
3. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine vs gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33): 5513-5518
4. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7): 1209-1214 (Pubitemid 41079833)
5. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25(16): 2212-2217 (Pubitemid 46954645)
6. Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Chen J, Mizumoto K, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Cheng A, Okusaka T (2011) Randomized phase III study of gemcitabine plus S-1 (GS) vs S-1 vs gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 29(15 suppl): 4007
7. Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K (2011) Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology 80(1-2): 97-101
8. Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS (2009) S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 39(1): 49-53
9. Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH (2009) Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 64(4): 707-713
10. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960-1966 (Pubitemid 46972777)
11. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E (2009) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63(2): 313-319
12. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K (2010a) Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas 39(7): 989-993
13. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M (2009) A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 77(5): 300-303
14. Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Omata M, Koike K (2010b) Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol 40(8): 774-780
15. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H (2005) Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92(12): 2134-2139 (Pubitemid 40966247)
16. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94(11): 1575-1579 (Pubitemid 43924916)
17. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10): 1073-1081
18. Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH (2010) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 65(3): 527-536
19. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61(4): 615-621
20. Omuro Y, Ikari T, Ishii H, Ozaka M, Suyama M, Matsumura Y, Itoi T, Egawa N, Yano S, Hanada K, Kimura Y, Ukita T, Ishida Y, Tani M, Ohoka S, Hirose Y, Hijioka S, Watanabe R, Ikeda T, Nakajima T, Organization JCCR (2011) A randomized phase II study of gemcitabine plus S-1 vs gemcitabine alone in patients with unresectable pancreatic cancer. J Clin Oncol 29(15 suppl): 4029
21. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V (2005) Gemcitabine vs cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6(6): 369-376 (Pubitemid 40753742)
22. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O (2011) Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 67(2): 249-254
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
24. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K (2005a) A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69(5): 421-427 (Pubitemid 41797919)
25. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2005b) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68(2-3): 171-178 (Pubitemid 41158973)